An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission

Kairat Tabynov; Nurkeldi Turebekov; Meruert Babayeva; Gleb Fomin; Toktassyn Yerubayev; Tlektes Yespolov; Lei Li; Gourapura J. Renukaradhya; Nikolai Petrovsky; Kaissar Tabynov

doi:10.1038/s41541-022-00450-8

An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission

Kairat Tabynov, Nurkeldi Turebekov, Meruert Babayeva, Gleb Fomin, Toktassyn Yerubayev, Tlektes Yespolov, Lei Li, Gourapura J. Renukaradhya, Nikolai Petrovsky, Kaissar Tabynov

College of Medicine and Public Health

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

2 Downloads (Pure)

Abstract

Recombinant protein approaches offer major promise for safe and effective vaccine prevention of SARS-CoV-2 infection. We developed a recombinant spike protein vaccine (called NARUVAX-C19) and characterized its ability when formulated with a nanoemulsion adjuvant to induce anti-spike antibody and T-cell responses and provide protection including against viral transmission in rodent. In mice, NARUVAX-C19 vaccine administered intramuscularly twice at 21-day interval elicited balanced Th1/Th2 humoral and T-cell responses with high titers of neutralizing antibodies against wild-type (D614G) and delta (B.1.617.2) variants. In Syrian hamsters, NARUVAX-C19 provided complete protection against wild-type (D614G) infection and prevented its transmission to naïve animals (n = 2/group) placed in the same cage as challenged animals (n = 6/group). The results contrasted with only weak protection seen with a monomeric spike receptor-binding domain (RBD) vaccine even when formulated with the same adjuvant. These encouraging results warrant the ongoing development of this COVID-19 vaccine candidate.

Original language	English
Article number	24
Number of pages	10
Journal	npj Vaccines
Volume	7
Issue number	1
DOIs	https://doi.org/10.1038/s41541-022-00450-8
Publication status	Published - 23 Feb 2022

Keywords

Protein vaccines
Viral infection

Access to Document

10.1038/s41541-022-00450-8Licence: CC BY

Final published versionFinal published version, 3.01 MBLicence: CC BY

Cite this

@article{19d36ad6124743e2b59e13ddab1d6cbf,

title = "An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission",

abstract = "Recombinant protein approaches offer major promise for safe and effective vaccine prevention of SARS-CoV-2 infection. We developed a recombinant spike protein vaccine (called NARUVAX-C19) and characterized its ability when formulated with a nanoemulsion adjuvant to induce anti-spike antibody and T-cell responses and provide protection including against viral transmission in rodent. In mice, NARUVAX-C19 vaccine administered intramuscularly twice at 21-day interval elicited balanced Th1/Th2 humoral and T-cell responses with high titers of neutralizing antibodies against wild-type (D614G) and delta (B.1.617.2) variants. In Syrian hamsters, NARUVAX-C19 provided complete protection against wild-type (D614G) infection and prevented its transmission to na{\"i}ve animals (n = 2/group) placed in the same cage as challenged animals (n = 6/group). The results contrasted with only weak protection seen with a monomeric spike receptor-binding domain (RBD) vaccine even when formulated with the same adjuvant. These encouraging results warrant the ongoing development of this COVID-19 vaccine candidate.",

keywords = "Protein vaccines, Viral infection",

author = "Kairat Tabynov and Nurkeldi Turebekov and Meruert Babayeva and Gleb Fomin and Toktassyn Yerubayev and Tlektes Yespolov and Lei Li and Renukaradhya, {Gourapura J.} and Nikolai Petrovsky and Kaissar Tabynov",

year = "2022",

month = feb,

day = "23",

doi = "10.1038/s41541-022-00450-8",

language = "English",

volume = "7",

journal = "npj Vaccines",

issn = "2059-0105",

number = "1",

}

TY - JOUR

T1 - An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission

AU - Tabynov, Kairat

AU - Turebekov, Nurkeldi

AU - Babayeva, Meruert

AU - Fomin, Gleb

AU - Yerubayev, Toktassyn

AU - Yespolov, Tlektes

AU - Li, Lei

AU - Renukaradhya, Gourapura J.

AU - Petrovsky, Nikolai

AU - Tabynov, Kaissar

PY - 2022/2/23

Y1 - 2022/2/23

N2 - Recombinant protein approaches offer major promise for safe and effective vaccine prevention of SARS-CoV-2 infection. We developed a recombinant spike protein vaccine (called NARUVAX-C19) and characterized its ability when formulated with a nanoemulsion adjuvant to induce anti-spike antibody and T-cell responses and provide protection including against viral transmission in rodent. In mice, NARUVAX-C19 vaccine administered intramuscularly twice at 21-day interval elicited balanced Th1/Th2 humoral and T-cell responses with high titers of neutralizing antibodies against wild-type (D614G) and delta (B.1.617.2) variants. In Syrian hamsters, NARUVAX-C19 provided complete protection against wild-type (D614G) infection and prevented its transmission to naïve animals (n = 2/group) placed in the same cage as challenged animals (n = 6/group). The results contrasted with only weak protection seen with a monomeric spike receptor-binding domain (RBD) vaccine even when formulated with the same adjuvant. These encouraging results warrant the ongoing development of this COVID-19 vaccine candidate.

AB - Recombinant protein approaches offer major promise for safe and effective vaccine prevention of SARS-CoV-2 infection. We developed a recombinant spike protein vaccine (called NARUVAX-C19) and characterized its ability when formulated with a nanoemulsion adjuvant to induce anti-spike antibody and T-cell responses and provide protection including against viral transmission in rodent. In mice, NARUVAX-C19 vaccine administered intramuscularly twice at 21-day interval elicited balanced Th1/Th2 humoral and T-cell responses with high titers of neutralizing antibodies against wild-type (D614G) and delta (B.1.617.2) variants. In Syrian hamsters, NARUVAX-C19 provided complete protection against wild-type (D614G) infection and prevented its transmission to naïve animals (n = 2/group) placed in the same cage as challenged animals (n = 6/group). The results contrasted with only weak protection seen with a monomeric spike receptor-binding domain (RBD) vaccine even when formulated with the same adjuvant. These encouraging results warrant the ongoing development of this COVID-19 vaccine candidate.

KW - Protein vaccines

KW - Viral infection

UR - http://www.scopus.com/inward/record.url?scp=85125461457&partnerID=8YFLogxK

U2 - 10.1038/s41541-022-00450-8

DO - 10.1038/s41541-022-00450-8

M3 - Article

AN - SCOPUS:85125461457

VL - 7

JO - npj Vaccines

JF - npj Vaccines

SN - 2059-0105

IS - 1

M1 - 24

ER -

An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this